Lamivudine Articles
Zeffix effective for HBV in children
24 April 2001
Gilead's adefovir effective in HBV
24 April 2001
Mali, Cameroon to get cheap HIV/AIDS drugs
11 April 2001
GSK: "Combivir's price goes no lower"
9 April 2001
Drug majors cut AIDS drug prices further
7 March 2001
Cipla talks with WHO over AIDS drug offer
1 March 2001
10 countries to get Cipla's AIDS drugs
26 February 2001
Kenyan moves to buy cheap AIDS drugs
26 February 2001
GSK "surprise" at SA HIV/AIDS drugs claim
23 February 2001
GlaxoSmithKline starts life in 2001 on a strong financial footing
21 February 2001
Cipla talks with MNCs over HIV drug offer
13 February 2001
Earnings increase 41% at BioChem Pharma
1 February 2001
GSK's Trizivir cleared in EU for HIV
9 January 2001
Warnings issued on use of B-MS' antiretrovirals in pregnancy
8 January 2001
US PA&I invalidates Emory Epivir patent
28 December 2000
Pfizer forecasts strong revenue growth in 2001-2002 at R&D meeting
14 December 2000
Shire Pharmaceuticals and BioChem Pharma announce $4 billion merger
11 December 2000
S Africa OKs generic Diflucan imports
1 December 2000
Vertex and GW start pivotal trials of amprenavir prodrug in HIV
29 November 2000
GW
22 November 2000
BioChem Pharma set to merge?
20 November 2000
Cipla suspends HIV drug exports to Ghana
16 November 2000
GW wins FDA approval for Trizivir
16 November 2000
Antiretrovirals backed by WHO for HIV MTCT
10 November 2000
Biochem Pharma to acquire CliniChem
30 October 2000
Gilead Sciences boosted on tenefovir DF resistance data
25 October 2000
Go-ahead granted for lamivudine plus TCM trials
10 October 2000
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
BioChem and GW get Japanese OK for Zefix
28 September 2000
HIV/AIDS therapy sales forecasts to 2009
3 August 2000
Triangle's DAPD shows promise in resistant HIV
20 July 2000
GW's anti-HIV drug Trizivir backed in EU
18 July 2000
BI offers free Viramune to developing countries
7 July 2000
Triangle seeks to lift halt on HIV drug
13 June 2000
World sale forecasts for antivirals to 2008
7 June 2000
BioChem Pharma earnings up 34%
3 May 2000
BI's Viramune shows efficacy in advanced HIV
3 February 2000
Abbott's ABT-378/r, efficacy in PI-resistant patients
3 February 2000
First clinical data for Agouron's capravirine
2 February 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
BioChem Pharma expects sales and royalties to grow 20% in 2000
12 January 2000
GW seeks backing for Trizivir, new HIV combo
20 December 1999
Zeffix approved in Taiwan for hepatitis B
2 November 1999
BioChem Pharma profits up 17%
29 October 1999
BioChem/GW's Zeffix effective in chronic hep B
27 October 1999
US Biosciences halts lodenosine HIV trial after death of patient
15 October 1999
Sustiva, Combivir "beat HIV non-compliance"
13 October 1999
New generation of anti-HIV drugs unveiled at ICAAC
13 October 1999
Remune combo trial
27 September 1999
Glaxo sells plant to AHP for $60 million
26 August 1999
BioChem succeeds in patent war with Emory
12 August 1999
Sharp earnings rise at BioChem Pharma
2 August 1999
GW gains EU approval for Ziagen
13 July 1999
New data with BioChem's Zeffix in Hep B
8 July 1999
BioChem Pharma posts 39% revenue rise
5 May 1999
South Africa tells AIDS drugmakers:cut your prices
30 April 1999
CPMP backs approval of lamivudine for HBV
29 April 1999
GW's Zeffix trial data
15 April 1999
BioChem Pharma starts Phase II troxacitabine
8 April 1999
Sustiva cleared in Canada for HIV
29 March 1999
New trials support role of nevirapine in HIV
29 March 1999
Sustiva-based HIV therapy assessed
18 February 1999
US HIV conference data in brief
4 February 1999
Epivir boosts earnings at BioChem Pharma
3 February 1999
Abbott's ABT-378 potent against HIV
2 February 1999
Low compliance could fuel AIDS epidemic
26 January 1999
Lamivudine Approved For Hep B In China
14 January 1999
G-W's Ziagen approved in USA
21 December 1998
Canada Approve Combivir for HIV Infection
9 December 1998
FDA Approve Epivir For Chronic Hepatitis B
9 December 1998
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
